ArticleFrontiers in pharmacology2026
The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Supported by evidence of efficacy and safety from the landmark HEPATORCH trial, the combination therapy of toripalimab and bevacizumab (TORI + Bev) has been adopted into the Chinese Society of Clinical Oncology (CSCO) clinical guidelines for advanced hepatocellular carcinoma (HCC). The economic viability of this regimen, however, has yet to be assessed. Methods: This economic evaluation used a partitioned survival model (PartSA) over a 10-year horizon. Overall survival data from the HEPATORCH trial were incorporated into the model to compare the cost-effectiveness of first-line TORI plus bevacizumab (TORI + Bev) Results: Compared with sorafenib, the TORI plus bevacizumab regimen demonstrated greater health benefits (1.62 QALYs vs. 1.27 QALYs). However, due to its higher treatment costs, the incremental cost-effectiveness ratio (ICER) for TORI plus bevacizumab reached $67,352.09 per QALY under originator pricing and $65,300.63 per QALY under generic pricing. Probabilistic sensitivity analysis indicated that, when using three times China's GDP Conclusion: TORI + Bev is unlikely to be cost effective compared with sorafenib for the first-line treatment of advanced HCC in China. Reducing the price of bevacizumab can increase the possibility of it being cost effective in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.